Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 10.19 | -2.39% | -0.25 |
Earnings due: Feb 11
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical IRWD trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Resistance | Bearish | -2.39% | |
Lower Bollinger Band Walk | Weakness | -2.39% | |
Lower Bollinger Band Touch | Weakness | -2.39% | |
Oversold Stochastic | Weakness | -2.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 3% | about 18 hours ago | |
Outside Day | about 21 hours ago | |
Down 2 % | about 21 hours ago | |
Fell Below Lower Bollinger Band | about 21 hours ago | |
Fell Below Previous Day's Low | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 02/11/2021
Ironwood Pharmaceuticals, Inc. Description
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Gastrointestinal Therapeutic Product Cardiovascular Disease Therapeutic Products Nervous System Disorders Central Nervous System Disorders Peptides Gastroenterology Vascular Diseases Cardiovascular Diseases Macau Gastrointestinal Disease Gastrointestinal Diseases European Union Irritable Bowel Syndrome Constipation Digestive Diseases Gastrointestinal Disorders Laxatives Human Therapeutic Products Linaclotide
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.23 |
52 Week Low | 7.99 |
Average Volume | 1,316,456 |
200-Day Moving Average | 10.45 |
50-Day Moving Average | 11.57 |
20-Day Moving Average | 11.16 |
10-Day Moving Average | 10.83 |
Average True Range | 0.39 |
ADX | 29.23 |
+DI | 10.79 |
-DI | 27.17 |
Chandelier Exit (Long, 3 ATRs ) | 10.92 |
Chandelier Exit (Short, 3 ATRs ) | 11.29 |
Upper Bollinger Band | 12.17 |
Lower Bollinger Band | 10.15 |
Percent B (%b) | 0.02 |
BandWidth | 18.05 |
MACD Line | -0.33 |
MACD Signal Line | -0.19 |
MACD Histogram | -0.1383 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.82 | ||||
Resistance 3 (R3) | 10.87 | 10.70 | 10.72 | ||
Resistance 2 (R2) | 10.70 | 10.54 | 10.68 | 10.68 | |
Resistance 1 (R1) | 10.45 | 10.44 | 10.37 | 10.40 | 10.64 |
Pivot Point | 10.28 | 10.28 | 10.24 | 10.26 | 10.28 |
Support 1 (S1) | 10.03 | 10.12 | 9.95 | 9.98 | 9.74 |
Support 2 (S2) | 9.86 | 10.02 | 9.84 | 9.70 | |
Support 3 (S3) | 9.61 | 9.86 | 9.67 | ||
Support 4 (S4) | 9.56 |